Clinical trialNCT04516746CompletedPhase 3Interventional

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

SponsorAstraZenecaEnrollment32,450COVID-19SARS-CoV-2

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ann Falsey, MD
University of Rochester
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Magda Sobieszczyk, MD
Columbia University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

84 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Chile

Research Site
Quillota, Chile
Research Site
Santiago, Chile
Research Site
Santiago, Chile

Peru

Research Site
Callao, Peru
Research Site
Lima, Peru
Research Site
Lima Cercado, Peru

United States

Research Site
Phoenix, Arizona, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Berkeley, California, United States
Research Site
El Centro, California, United States
Research Site
Los Angeles, California, United States
Research Site
Los Angeles, California, United States
Research Site
San Diego, California, United States
Research Site
San Diego, California, United States
Research Site
San Francisco, California, United States
Research Site
San Francisco, California, United States
Research Site
Torrance, California, United States
Research Site
Denver, Colorado, United States
Research Site
Danbury, Connecticut, United States
Research Site
Coral Gables, Florida, United States
Research Site
Lake Worth, Florida, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Honolulu, Hawaii, United States
Research Site
Meridian, Idaho, United States
Research Site
Chicago, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Ankeny, Iowa, United States
Research Site
Fairway, Kansas, United States
Research Site
Kansas City, Kansas, United States
Research Site
Wichita, Kansas, United States
Research Site
Wichita, Kansas, United States
Research Site
Lexington, Kentucky, United States
Research Site
Lake Charles, Louisiana, United States
Research Site
Monroe, Louisiana, United States
Research Site
Baltimore, Maryland, United States
Research Site
Baltimore, Maryland, United States
Research Site
Bethesda, Maryland, United States
Research Site
Boston, Massachusetts, United States

44 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AZD-1222Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Aug 2020
Primary completion: 5 Mar 2021
Completion: 10 Feb 2023
Last update posted: 5 Feb 2024
Registered enrollment: 32,450
Registry id: NCT04516746

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-005226-28

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.